Novamind increases its strategic investment in Bionomics Limited, in support of its plans for a Phase IIb clinical trial for PTSD.
INVESTOR PROFILE | Ionic Brands
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
52-Week
Range N/A
Range N/A
Current
Outstanding 108,436,715
Outstanding 108,436,715
Warrants
Options
Fully Diluted
Market Cap.
14,639,000
14,639,000
IONIC BRANDS (CSE: IONC) has a premium portfolio of cannabis concentrate consumer brands. Ionic Brands is one of the top selling concentrate company in Washington State.
Company Brief
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Highlights
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
In The News
Ionic Is Changing the Face of Cannabis and Creating a Social Revolution
It’s all in the URL: Ionic.social. “We believe our products are best when enjoyed in a social setting,” said co-founder Christian Struzan.
READ MORE
Marijuana Vaping Is The Most Explosive Growth Play In Marijuana Today
“Nobody smokes marijuana anymore, they vape it.” - New York Times That's not quite true. But it will be soon.
READ MORE
How To Invest In Marijuana Vaping
The marijuana vaporization products (or just "vape") market is set to explode in 2019.
READ MORE
Related Articles
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
A New England Journal of Medicine study found CMPS's COMP360 psilocybin therapy performed better than the leading antidepressant.
MINDCURE (CSE: MCUR | OTC: MCURF) Announces The Addition Of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience In Medical Psychoactive Segment
Mr. Herrera, Who Will Join The Company As Its Vice President Of Growth And Strategic Partnerships, Has 15+ Years Of Global Life Sciences Experience And Will Help To Drive MINDCURE’s Commercial Focus And Strategic Partnerships
Psychedelic Drugs: The Cure For ‘COVID Isolation Syndrome’?
A recent study shows HALF of all adults already experiencing anxiety due to the social isolation from COVID-19 lockdowns. COVID Isolation Syndrome.
Uber Will ‘Absolutely’ Explore Marijuana Deliveries When Federal Prohibition Ends, CEO Says
The CEO of Uber said on Monday that the ride share company will “absolutely” explore adding marijuana deliveries to its services when federal prohibition ends.
GH Research Announces Closing of $125 Million Oversubscribed Series B Financing
Ireland-based GH Research has just raised $125 million in an oversubscribed Series B financing round.